NasdaqGM:FOLDBiotechs
A Look at Amicus Therapeutics's Valuation as Profitability and Strong Guidance Signal Financial Turnaround
Amicus Therapeutics (FOLD) has reported third-quarter results showing a swing to net income after a loss just a year ago. The company also reaffirmed guidance for solid revenue growth through the rest of 2025. Investors are closely watching these signs of financial improvement.
See our latest analysis for Amicus Therapeutics.
Following these upbeat earnings, Amicus Therapeutics’ share price is up nearly 29% over the past three months, showing meaningful momentum as investors react to its...